Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590

Immunity, Inflammation, and Cancer

Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755

Pattern Recognition Receptors and Inflammation

Takeuchi, O., & Akira, S. (2010) · Cell · doi:10.1016/j.cell.2010.01.022 · Cited by 8,895

Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474

Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056

Taking dendritic cells into medicine

Steinman, R. M., & Banchereau, J. (2007) · Nature · doi:10.1038/nature06175 · Cited by 2,162

The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity

Zhu, C., Anderson, A. C., Schubart, A., Xiong, H., Imitola, J., Khoury, S. J., Zheng, X. X., Strom, T. B., & Kuchroo, V. K. (2005) · Nature Immunology · doi:10.1038/ni1271 · Cited by 2,057

Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells

Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977

Immunosuppressive Strategies that are Mediated by Tumor Cells

Rabinovich, G. A., Gabrilovich, D. I., & Sotomayor, E. M. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,747

HMGB1 is a therapeutic target for sterile inflammation and infection

Andersson, U., & Tracey, K. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101323 · Cited by 1,437

Melanoma-infiltrating dendritic cells

Klarquist, J. S., & Janssen, E. M. (2012) · OncoImmunology · doi:10.4161/onci.22660 · Cited by 31

Hemidesmus indicus induces immunogenic death in human colorectal cancer cells

Turrini, E., Catanzaro, E., Muraro, M. G., Governa, V., Trella, E., Mele, V., Calcabrini, C., Morroni, F., Sita, G., Hrelia, P., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25325 · Cited by 29

A programmable releasing versatile hydrogel platform boosts systemic immune responses via sculpting tumor immunogenicity and reversing tolerogenic dendritic cells

Fu, W., Li, X., Li, Y., Luo, R., Ou, C., Huang, D., Liang, X., You, Y., Wu, Q., & Gong, C. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122444 · Cited by 27

Immunotherapeutic strategies beyond the PD-1/PD-L1 pathway in head and neck squamous cell carcinoma – A scoping review on current developments in agents targeting TIM-3, TIGIT, LAG-3, and VISTA

Struckmeier, A., Gosau, M., & Smeets, R. (2024) · Oral Oncology · doi:10.1016/j.oraloncology.2024.107145 · Cited by 27

The role of immune checkpoints PD-1 and CTLA-4 in cardiovascular complications leading to heart failure

Huang, S., Kang, Y., Liu, T., Xiong, Y., Yang, Z., & Zhang, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1561968 · Cited by 28

Coinhibitory molecules in cancer biology and therapy

D, S. M. M., Benna, C., & Pilati, P. (2013) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.01.003 · Cited by 27

Combined blockade of Tim-3 and MEK inhibitor enhances the efficacy against melanoma

Liu, Y., Cai, P., Wang, N., Zhang, Q., Chen, F., Shi, L., Zhang, Y., Wang, L., & Hu, L. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.01.128 · Cited by 29

Nanobodies Enhancing Cancer Visualization, Diagnosis and Therapeutics

Naidoo, D. B., & Chuturgoon, A. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189778 · Cited by 28

Differential expression of HAVCR2 gene in pan-cancer: A potential biomarker for survival and immunotherapy

Li, H., Yang, D., Hao, M., & Liu, H. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.972664 · Cited by 27

Dendritic Cells: The Long and Evolving Road towards Successful Targetability in Cancer

Marmonti, E., Oliva, J., & Haymaker, C. (2022) · Cells · doi:10.3390/cells11193028 · Cited by 29

T-cell immunoglobulin and mucin-domain containing-3 (TIM-3): Solving a key puzzle in autoimmune diseases

Chen, H., Zha, J., Tang, R., & Chen, G. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110418 · Cited by 27

Increased Plasma Cell-Free DNA Level during HTNV Infection: Correlation with Disease Severity and Virus Load

Yi, J., Zhang, Y., Zhang, Y., Ma, Y., Zhang, C., Li, Q., Liu, B., Liu, Z., Liu, J., Zhang, X., et al. (2014) · Viruses · doi:10.3390/v6072723 · Cited by 27

Targeting Damage-Associated Molecular Pattern Molecules (DAMPs) and DAMP Receptors in Melanoma

Boone, B. A., & Lotze, M. T. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-727-3_29 · Cited by 27

MiR-let-7e inhibits invasion and magration and regulates HMGB1 expression in papillary thyroid carcinoma

Ding, C., Yu, H., Shi, C., Shi, T., Qin, H., & Cui, Y. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.11.057 · Cited by 27

Unravelling T cell exhaustion through co‐inhibitory receptors and its transformative role in cancer immunotherapy

Xiang, S., Li, S., & Xu, J. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70345 · Cited by 28

The dynamic role of immune checkpoint molecules in diagnosis, prognosis, and treatment of head and neck cancers

Mestiri, S., El-Ella, D. M. A., Fernandes, Q., Bedhiafi, T., Almoghrabi, S., Akbar, S., Inchakalody, V. P., Assami, L., Anwar, S., Shahab Uddin, M. S., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.116095 · Cited by 28

The Common Costimulatory and Coinhibitory Signaling Molecules in Head and Neck Squamous Cell Carcinoma

Liao, P., Wang, H., Tang, Y., Tang, Y.-J., & Liang, X. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02457 · Cited by 27

Microglia activity modulated by T cell Ig and mucin domain protein 3 (Tim-3)

Wang, H., Zhu, X., Qin, L., Qian, H.-J., & Wang, Y. (2014) · Cellular Immunology · doi:10.1016/j.cellimm.2014.12.005 · Cited by 26

TIM3 expression on tumor cells predicts response to anti-PD-1 therapy for renal cancer

Kato, R., Jinnouchi, N., Tuyukubo, T., Ikarashi, D., Matsuura, T., Maekawa, S., Kato, Y., Kanehira, M., Takata, R., Ishida, K., et al. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100918 · Cited by 26

The ‘Danse Macabre’—Neutrophils the Interactive Partner Affecting Oral Cancer Outcomes

Hadjigol, S., Shah, B. A., & O’brien-simpson, N. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.894021 · Cited by 26

Mechanistic rationales for combining immunotherapy with radiotherapy

Chi, A., & Nguyen, N. P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1125905 · Cited by 25

Down-regulated expression of Tim-3 promotes invasion and metastasis of colorectal cancer cells

SUN, Q. Y., QU, C. H., Liu, J. Q., ZHANG, P., & Yao, J. (2016) · Neoplasma · doi:10.4149/neo_2017_112 · Cited by 24

Targeting the dendritic cell-T cell axis to develop effective immunotherapies for glioblastoma

Gardam, B., Gargett, T., Brown, M. P., & Ebert, L. M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1261257 · Cited by 25

Persistent Activation of the P2X7 Receptor Underlies Chronic Inflammation and Carcinogenic Changes in the Intestine

Santana, P. T., de Lima, I. S., Souza, K. C. D. S. E., Barbosa, P. H. S., & de Souza, H. S. P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252010874 · Cited by 26

Tipping the balance: inhibitory checkpoints in intestinal homeostasis

Joosse, M. E., Nederlof, I., Walker, L. S. K., & Samsom, J. N. (2018) · Mucosal Immunology · doi:10.1038/s41385-018-0113-5 · Cited by 24

TIM-3 drives temporal differences in restimulation-induced cell death sensitivity in effector CD8+ T cells in conjunction with CEACAM1

Lake, C. M., Voss, K., Bauman, B. M., Pohida, K., Jiang, T., Dveksler, G. S., & Snow, A. L. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03689-6 · Cited by 23

Checkpoints and immunity in cancers: Role of GNG12

Alausa, A. O., Victor, U. C., Fadahunsi, O. S., Owolabi, N., Adeniji, A., Olatinwo, M., Ogunlana, A. T., Olaleke, B., Balogun, T. A., Ogundepo, S., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106242 · Cited by 24

Design and Evaluation of TIM-3-CD28 Checkpoint Fusion Proteins to Improve Anti-CD19 CAR T-Cell Function

Blaeschke, F., Ortner, E., Stenger, D., Mahdawi, J., Apfelbeck, A., Habjan, N., Weißer, T., Kaeuferle, T., Willier, S. M., Kobold, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.845499 · Cited by 24

Mesenchymal Stem Cell Transplantation Alleviates Sjögren's Syndrome Symptoms Through Tim-3 Signaling in T Cells

Sun, T., Liu, S., Yang, G., Zhu, R., Li, Z., Yao, G., Chen, H., & Sun, L. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109152 · Cited by 23

The therapeutic potential of immunotherapy in the treatment of breast cancer: Rational strategies and recent progress

Javid, H., Attarian, F., Saadatmand, T., Rezagholinejad, N., Mehri, A., Amiri, H., & Karimi‐Shahri, M. (2023) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30402 · Cited by 23

Targeting immune checkpoints in anti-neutrophil cytoplasmic antibodies associated vasculitis: the potential therapeutic targets in the future

Pan, M., Zhao, H., Jin, R., Leung, P. S. C., & Shuai, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1156212 · Cited by 24

Sabatolimab ( MBG453 ) model‐informed drug development for dose selection in patients with myelodysplastic syndrome/acute myeloid leukemia and solid tumors

Xu, S., Zhang, N., Rinne, M. L., Sun, H., & Stein, A. M. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12962 · Cited by 23

Interferon response factor 3 is crucial to poly-I:C induced NK cell activity and control of B16 melanoma growth

Moore, T. C., Kumm, P. M., Brown, D. M., & Petro, T. M. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.12.022 · Cited by 23

Involvement of HMGB1 in Resistance to Tumor Vessel-Targeted, Monoclonal Antibody-Based Immunotherapy

Pistoia, V., & Pezzolo, A. (2016) · Journal of Immunology Research · doi:10.1155/2016/3142365 · Cited by 23

Translational Implication of Galectin-9 in the Pathogenesis and Treatment of Viral Infection

Lai, J., Luo, S., Wang, M., & Ho, L. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102108 · Cited by 23

Harnessing immune checkpoints in myeloid lineage cells for cancer immunotherapy

Park, S., & Kim, I. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.03.018 · Cited by 23

First-in-human phase I open-label study of the anti–TIM-3 monoclonal antibody INCAGN02390 in patients with select advanced or metastatic solid tumors

Gutierrez, M. E., Tang, S., Powderly, J. D., Balmanoukian, A. S., Hoyle, P., Dong, Z., Cheng, L. L., Gong, X., Janik, J. E., Bourayou, N., et al. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf144 · Cited by 22

TIM-3 expression in lymphoma cells predicts chemoresistance in patients with adult T-cell leukemia/lymphoma

Horlad, H., Ohnishi, K., Ma, C., Fujiwara, Y., Niino, D., Ohshima, K., Jinushi, M., Matsuoka, M., Takeya, M., & Komohara, Y. (2016) · Oncology Letters · doi:10.3892/ol.2016.4774 · Cited by 22

Role of TIM-3 in ovarian cancer

Xu, Y., Zhang, H., Huang, Y., Rui, X., & Zheng, F. (2017) · Clinical & Translational Oncology · doi:10.1007/s12094-017-1656-8 · Cited by 23

Signal Transduction Via Co-stimulatory and Co-inhibitory Receptors

Ogawa, S., & Abe, R. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9717-3_4 · Cited by 22

Immune Checkpoints and Innate Lymphoid Cells—New Avenues for Cancer Immunotherapy

Jacquelot, N., Ghaedi, M., Warner, K., Chung, D. C., Crome, S. Q., & Ohashi, P. S. (2021) · Cancers · doi:10.3390/cancers13235967 · Cited by 22

Insights into Modern Therapeutic Approaches in Pediatric Acute Leukemias

Panuciak, K., Margas, M., Makowska, K., & Lejman, M. (2022) · Cells · doi:10.3390/cells11010139 · Cited by 22

The role of HMGB1 in inflammatory skin diseases

Satoh, T. K. (2022) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2022.07.005 · Cited by 22

T Cell Immunoglobulin and Mucin Domain 3 (TIM-3) in Cutaneous Melanoma: A Narrative Review

Cazzato, G., Cascardi, E., Colagrande, A., Lettini, T., Filosa, A., Arezzo, F., Lupo, C., Casatta, N., Loizzi, V., Pellegrini, C., et al. (2023) · Cancers · doi:10.3390/cancers15061697 · Cited by 22

T Cell CEACAM1–TIM-3 Crosstalk Alleviates Liver Transplant Injury in Mice and Humans

Kojima, H., Kadono, K., Hirao, H., Dery, K. J., Torgerson, T., Yao, S., Kaldas, F. M., Farmer, D. G., Blumberg, R. S., & Kupiec‐Weglinski, J. W. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.07.004 · Cited by 22

Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross‐priming

Luri‐Rey, C., Gomis, G., Glez‐Vaz, J., Manzanal, A., Riaño, A. M., Rodriguez-Ruiz, M. E., Teijeira, Á., & Melero, I. (2023) · Immunological Reviews · doi:10.1111/imr.13281 · Cited by 23

Alternative Checkpoints as Targets for Immunotherapy

Pant, A., Medikonda, R. T., & Lim, M. K. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00983-y · Cited by 22

The redox-sensitive protein HMGB1: intracellular and extracellular roles

Kwak, M. S., Jung, S. F., Park, I. H., & Shin, J. (2026) · Experimental & Molecular Medicine · doi:10.1038/s12276-026-01640-3 · Cited by 21

Nucleic acid sensing and beyond: virtues and vices of high‐mobility group box 1

Yanai, H., & Taniguchi, T. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12285 · Cited by 21

Impact of HMGB1 on cancer development and therapeutic insights focused on CNS malignancy

Patra, S., Roy, P., Dey, A., & Mandal, M. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189105 · Cited by 21

Disruption of a Regulatory Network Consisting of Neutrophils and Platelets Fosters Persisting Inflammation in Rheumatic Diseases

Maugeri, N., Rovere, P. Q., & Manfredi, A. A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00182 · Cited by 21

Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma

Aris, M., Mordoh, J., & Barrio, M. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01024 · Cited by 21

Tim-3 Promotes Listeria monocytogenes Immune Evasion by Suppressing Major Histocompatibility Complex Class I

Wang, Z., Li, G., Dou, S., Zhang, Y., Liu, Y., Zhang, J., Li, G., Hou, C., Wang, R., Shen, B., et al. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz512 · Cited by 21

Role of the Extracellular Traps in Central Nervous System

Wu, X., Zeng, H., Cai, L., & Chen, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.783882 · Cited by 22

Yin and yang of tumor inflammation: How innate immune suppressors shape the tumor microenvironments

Jinushi, M. (2013) · International Journal of Cancer · doi:10.1002/ijc.28626 · Cited by 22

Blockage of Galectin-receptor Interactions by α-lactose Exacerbates Plasmodium berghei-induced Pulmonary Immunopathology

Liu, J., Huang, S., Su, X., Song, J., & Lü, F. (2016) · Scientific Reports · doi:10.1038/srep32024 · Cited by 21

Inhibitory immune checkpoints suppress the surveillance of senescent cells promoting their accumulation with aging and in age-related diseases

Salminen, A. (2024) · Biogerontology · doi:10.1007/s10522-024-10114-w · Cited by 22

Sialoglycan recognition is a common connection linking acidosis, zinc, and HMGB1 in sepsis

Siddiqui, S. S., Dhar, C., Sundaramurthy, V., Sasmal, A., Yu, H., Bandala‐Sanchez, E., Li, M., Zhang, X., Chen, X., Harrison, L. C., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2018090118 · Cited by 20

Novel immune targets for the treatment of triple-negative breast cancer

Corti, C., Nicolò, E., & Curigliano, G. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.2006187 · Cited by 21

Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)

Bewersdorf, J. P., Xie, Z., Bejar, R. L., Borate, U., Boultwood, J., Brunner, A. M., Buckstein, R. J., Carraway, H. E., Churpek, J. E., Daver, N. G., et al. (2023) · Blood Reviews · doi:10.1016/j.blre.2023.101072 · Cited by 22

Identification of a novel small-molecule inhibitor targeting TIM-3 for cancer immunotherapy

Wu, M., Wu, A., Zhang, X., Li, Y., Li, B., Jin, S., Dong, Q., Niu, X., Zhang, L., Zhou, X., et al. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115583 · Cited by 20

Tim-3 Expression by Peripheral Natural Killer Cells and Natural Killer T Cells Increases in Patients with Lung Cancer - Reduction after Surgical Resection

Xu, L., Chen, D., He, J.-Y., Lu, C., Liu, X., Le, H., Wang, C.-Y., & Zhang, Y. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.22.9945 · Cited by 20

High mobility group box 1 as a biomarker in critically ill patients

Yagmur, E., Buendgens, L., Herbers, U., Beeretz, A., Weiskirchen, R., Koek, G. H., Trautwein, C., Tacke, F., & Koch, A. H. (2018) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.22584 · Cited by 20

Chrysin protects human osteoarthritis chondrocytes by inhibiting inflammatory mediator expression via HMGB1 suppression

Zhang, C., Yu, W., Huang, C., Ding, Q., Liang, C., Wang, L., Hou, Z., & Zhang, Z. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9724 · Cited by 20

Immunological and clinical implications of immune checkpoint blockade in human cancer

Kim, H., & Park, S. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01140-1 · Cited by 20

Immunological Targets for Immunotherapy: Inhibitory T Cell Receptors

Davar, D., & Zarour, H. M. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9773-2_2 · Cited by 20

Inhibiting the Unconventionals: Importance of Immune Checkpoint Receptors in γδ T, MAIT, and NKT Cells

Tardos, E. C., Baglioni, M. V., & Bekiaris, V. (2021) · Cancers · doi:10.3390/cancers13184647 · Cited by 20

Impact of LAG-3/FGL1 pathway on immune evasive contexture and clinical outcomes in advanced urothelial carcinoma

Yoshida, T., Nakamoto, T., Atsumi, N., Ohe, C., Sano, T., Yasukochi, Y., Tsuta, K., & Kinoshita, H. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009358 · Cited by 16

Immune checkpoint blockade for cancer therapy: current progress and perspectives

Ye, H., Liao, W., Pan, J., Shi, Y. P., & Wang, Q. (2025) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2300492 · Cited by 23

LAG3, TIM3 and TIGIT: New Targets for Immunotherapy and Potential Associations with Radiotherapy

Mireștean, C. C., Iancu, R. I., & Iancu, D. P. T. (2025) · Current Oncology · doi:10.3390/curroncol32040230 · Cited by 19

Targeting TIM-3 in solid tumors: innovations in the preclinical and translational realm and therapeutic potential

Saleh, R., Toor, S. M., & Elkord, E. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1841750 · Cited by 19

Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules?

Krzyżanowska, N., Wojas‐Krawczyk, K., Milanowski, J., & Krawczyk, P. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063087 · Cited by 19

High Mobility Group Protein B1 Decreases Surface Localization of PD-1 to Augment T-cell Activation

Gao, Q., Wang, S., Li, F., Lian, J., Cheng, S., Yue, D., Zhang, Z., Liu, S., Ren, F., Zhang, D., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0652 · Cited by 19

DNA-mediated proteolysis by neutrophil elastase enhances binding activities of the HMGB1 protein

Wang, X., Mayorga‐Flores, M., Bien, K. G., Bailey, A. O., & Iwahara, J. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102577 · Cited by 19

Biologic Functions of Hydroxychloroquine in Disease: From COVID-19 to Cancer

Niemann, B. R., Puleo, A., Stout, C., Markel, J., & Boone, B. A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122551 · Cited by 19

Immune checkpoints on T and NK cells in the context of HBV infection: Landscape, pathophysiology and therapeutic exploitation

Dumolard, L., Aspord, C., Marche, P. N., & Jílková, Z. M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1148111 · Cited by 22

Innate Immunity in Cancer Biology and Therapy

Zhang, Y., Xue, W., Xu, C., Nan, Y., Mei, S., Ju, D., Wang, S., & Zhang, X. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411233 · Cited by 19

Immunogenicity of cancer cells: An overview

Singh, T., Bhattacharya, M., Mavi, A. K., Gulati, A., Rakesh, Sharma, N. K., Gaur, S., & Kumar, U. (2023) · Cellular Signalling · doi:10.1016/j.cellsig.2023.110952 · Cited by 20

Extracellular vesicles derived from nasopharyngeal carcinoma induce the emergence of mature regulatory dendritic cells using a galectin‐9 dependent mechanism

Lefebvre, A., Trioën, C., Renaud, S., Laine, W., Hennart, B., Bouchez, C., Leroux, B., Allorge, D., Kluza, J., Werkmeister, E., et al. (2023) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12390 · Cited by 19

Advances in immunotherapy for breast cancer and feline mammary carcinoma: From molecular basis to novel therapeutic targets

Vilela, T., Valente, S., Correia, J., & Ferreira, F. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189144 · Cited by 19

On the Other Side: Manipulating the Immune Checkpoint Landscape of Dendritic Cells to Enhance Cancer Immunotherapy

Kong, B. Y., Bolton, H. A., Kim, J. W., Silveira, P. A., Fromm, P. D., & Clark, G. J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00050 · Cited by 19

Extracellular Release of HMGB1 as an Early Potential Biomarker for the Therapeutic Response in a Xenograft Model of Boron Neutron Capture Therapy

Imamichi, S., Chen, L., Ito, T., Tong, Y., Onodera, T., Sasaki, Y., Nakamura, S. N., Mauri, P., Sanada, Y., Igaki, H., et al. (2022) · Biology · doi:10.3390/biology11030420 · Cited by 19

Neoantigen-specific mRNA/DC vaccines for effective anticancer immunotherapy

Zhang, W., Guan, J., Wang, W., Chen, G., Li, F., & Lu, Z. (2024) · Genes and Immunity · doi:10.1038/s41435-024-00305-3 · Cited by 18

Igniting hope: Harnessing NLRP3 inflammasome-GSDMD-mediated pyroptosis for cancer immunotherapy

Li, L., Chen, L., & Sun, Z. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122951 · Cited by 18

Up-regulation of Tim-3 on T cells during acute simian immunodeficiency virus infection and on antigen specific responders

Amancha, P. K., Hong, J. J., Ansari, A. A., & Villinger, F. J. (2015) · AIDS · doi:10.1097/qad.0000000000000589 · Cited by 18

Profiling of primary peripheral blood‐ and monocyte‐derived dendritic cells using monoclonal antibodies from the HLDA10 Workshop in Wollongong, Australia

Autenrieth, S. E., Grimm, S., Rittig, S. M., Grünebach, F., Gouttefangeas, C., & Bühring, H. (2015) · Clinical & Translational Immunology · doi:10.1038/cti.2015.29 · Cited by 18

Quantitative assessment of TIM-3 polymorphisms and cancer risk in Chinese Han population

Gao, X., Yang, J., He, Y., & Zhang, J. (2016) · Oncotarget · doi:10.18632/oncotarget.8157 · Cited by 18

c-Src Suppresses Dendritic Cell Antitumor Activity via T Cell Ig and Mucin Protein-3 Receptor

Gujar, R., Maurya, N., Yadav, V., Gupta, M., Arora, S., Khatri, N., & Sen, P. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600104 · Cited by 18

The role of high‐mobility group protein box 1 in lung cancer

Wu, X., Chen, Y., Gong, C., & Pei, D. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26837 · Cited by 18

T cell immunoglobulin and mucin domain protein 3 inhibits glycolysis in RAW 264.7 macrophages through Hexokinase 2

Zhang, J., Hou, C., Dou, S., Li, G., Wang, Z., Liu, Y., Zhang, Y., Wang, R., Shen, B., & Han, G. (2020) · Scandinavian Journal of Immunology · doi:10.1111/sji.12981 · Cited by 18

Dendritic Cells in the Tumor Microenvironment

Kohli, K., & Pillarisetty, V. G. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-49270-0_2 · Cited by 18

TIM-3 regulates the NETs-mediated dendritic cell activation in myeloperoxidase-ANCA-associated vasculitis

Su, B., Mao, X., Yin, B., Chen, C., Zhang, M., Cui, T., & Hao, Y. (2021) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/6y0bjb · Cited by 18

Immunotherapy for the treatment of breast cancer

Ayala, M. A. M., Gottardo, M. F., Asad, A. S., Zuccato, C. F., Candia, A. J. N., Seilicovich, A., & Candolfi, M. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1324566 · Cited by 20

Comparative Analysis of Immune Checkpoint Molecules and Their Potential Role in the Transmissible Tasmanian Devil Facial Tumor Disease

Flies, A. S., Blackburn, N. B., Lyons, A. B., Hayball, J. D., & Woods, G. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00513 · Cited by 18

Human disease mutations highlight the inhibitory function of TIM-3

Dixon, K. O., Das, M., & Kuchroo, V. K. (2018) · Nature Genetics · doi:10.1038/s41588-018-0289-3 · Cited by 18

Tumor-infiltrating myeloid cells; mechanisms, functional significance, and targeting in cancer therapy

Toghraie, F. S., Bayat, M., Hosseini, M. S., & Ramezani, A. (2025) · Cellular Oncology · doi:10.1007/s13402-025-01051-y · Cited by 18

Immune cell-based therapies for solid tumors, current challenges and therapeutic advances

Torabi, S., Yekzaman, E., Taherkhani, S., Talachi, N., Khoshravesh, R., Khosravi, A., Salehi, M., Zarrabi, A., & Vosough, M. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02632-y · Cited by 18

Post-translational modifications of immune checkpoints: molecular mechanisms, tumor microenvironment remodeling, and therapeutic implications

Hsieh, H.-C., Ling, L.-L., & Yi-Ching, W. (2026) · Journal of Biomedical Science · doi:10.1186/s12929-025-01202-1 · Cited by 17

HSP90 inhibition acts synergistically with heat to induce a pro-immunogenic form of cell death in colon cancer cells

Mouratidis, P., & ter Haar, G. (2021) · International Journal of Hyperthermia · doi:10.1080/02656736.2021.1983036 · Cited by 17

HDACi promotes inflammatory remodeling of the tumor microenvironment to enhance epitope spreading and antitumor immunity

Nguyen, A., Ho, L., Hogg, R. A., Chen, L., Walsh, S. R., & Wan, Y. (2022) · Journal of Clinical Investigation · doi:10.1172/jci159283 · Cited by 17

Taming Dendritic Cells with TIM-3: Another Immunosuppressive Strategy Used by Tumors

Patel, J. M., Bozeman, E. N., & Selvaraj, P. (2012) · Immunotherapy · doi:10.2217/imt.12.126 · Cited by 45

Regulatory mechanisms of nucleic acid-mediated innate immune responses in the tumor microenvironment

Jinushi, M. (2012) · OncoImmunology · doi:10.4161/onci.21681 · Cited by 6

A Dendritic Cell-Derived Receptor Counteracts Antitumor Immunity

(2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-rw2012-123

Tumor immunity times out: TIM-3 and HMGB1

Tang, D., & Lotze, M. T. (2012) · Nature Immunology · doi:10.1038/ni.2396 · Cited by 116

TIM3 suppresses antitumour DCs

Alderton, G. K. (2012) · Nature reviews. Immunology · doi:10.1038/nri3288 · Cited by 4